Six Million Doses of Stamaril(TM) Vaccine Shipped in Record Time to
Brazil and Paraguay
LYON, France, Feb. 26 /CNW/ - Sanofi Pasteur, the vaccines division of
the Sanofi-aventis Group, announced today that six million doses of
Stamaril(TM)(1) yellow fever vaccine have been shipped upon UNICEF's request
to respond to the yellow fever epidemic in Latin America.
Brazil received four million doses of Stamaril(TM) vaccine early February
and an additional two million doses were shipped to Paraguay over the weekend
in response to urgent requests from Health Authorities.
"Sanofi Pasteur mobilized its teams to make this public health emergency
a priority," said Wayne Pisano, President and Chief Executive Officer of
Sanofi Pasteur. "This ability to respond to an emergency in record time
illustrates the company's commitment to global health."
The yellow fever vaccine that was provided to Brazil and Paraguay is part
of the UNICEF vaccine stockpile which is reserved for outbreak responses.
Sanofi Pasteur is currently the only vaccine supplier to the UNICEF yellow
fever vaccine stockpile.
Sanofi Pasteur is the largest provider of yellow fever vaccine worldwide
with 200 million doses of vaccine provided to 150 countries over the past 20
About yellow fever
Yellow fever is a viral disease that occurs in both rural and urban areas
in Africa and South America. There is no treatment for yellow fever, only
prevention by immunization. More than 200,000 people contract the disease and
30,000 people die from it each year. According to the WHO, over 30 countries
in Africa (with an estimated population of 508 million) are at risk. In the
Americas, yellow fever is endemic in nine South American countries and in
several Caribbean islands.
Sanofi-aventis, a leading global pharmaceutical company, discovers,
develops and distributes therapeutic solutions to improve the lives of
everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York
Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provided
more than 1.6 billion doses of vaccine in 2007, making it possible to immunize
more than 500 million people across the globe. A world leader in the vaccine
industry, sanofi pasteur offers the broadest range of vaccines protecting
against 20 infectious diseases. The company's heritage, to create vaccines
that protect life, dates back more than a century. Sanofi Pasteur is the
largest company entirely dedicated to vaccines. Every day, the company invests
more than EUR1 million in research and development. For more information,
please visit: http://www.sanofipasteur.com or http://www.sanofipasteur.us
Forward Looking Statements
This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These statements
include financial projections and estimates and their underlying assumptions,
statements regarding plans, objectives, intentions and expectations with
respect to future events, operations, products and services, and statements
regarding future performance. Forward-looking statements are generally
identified by the words "expects," "anticipates," "believes," "intends,"
"estimates," "plans" and similar expressions. Although sanofi-aventis'
management believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that forward-looking
information and statements are subject to various risks and uncertainties,
many of which are difficult to predict and generally beyond the control of
sanofi-aventis, that could cause actual results and developments to differ
materially from those expressed in, or implied or projected by, the
forward-looking information and statements. These risks and uncertainties
include those discussed or identified in the public filings with the SEC and
the AMF made by Sanofi-aventis, including those listed under "Risk Factors"
and "Cautionary Statement Regarding Forward-Looking Statements" in
sanofi-aventis' annual report on Form 20-F for the year ended December 31,
2006. Other than as required by applicable law, sanofi-aventis does not
undertake any obligation to update or revise any forward-looking information
(1) Stamaril is a trademark of Institut Pasteur
For further information:
For further information: Sanofi Pasteur, Pascal Barollier, Media
Relations, Tel: +33-4-37-37-51-41, email@example.com; Sanofi
Pasteur, Len Lavenda, Media Relations US, Tel: (570) 839-4446,
firstname.lastname@example.org; Media Relations: Tel.: +33-4-37-37-50-38, Media
Relations US: Tel.: (570) 839-4446